Erythropoietin reduces cisplatin-induced neurotoxicity without impairment of cytotoxic effects against tumor cells

International Journal of Oncology

Volumn 31, Issue 6, 2007, Pages 1547-1552

  Nowis, Dominika ^a   Legat, Magdalena ^a,b   Bil, Jacek ^a   Kurzaj, Zuzanna ^a   Issat, Tadeusz ^a   Stoklosa, Tomasz ^a   Mioduszewska, Barbara ^c   Kaczmarek, Leszek ^c   Jakóbisiak, Marek ^a   Golab, Jakub ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

Cisplatin; Erythropoietin; Neurotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ERYTHROPOIETIN; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL; ARTICLE; BRAIN CORTEX; CELL CULTURE; CELL PROTECTION; CELL SURVIVAL; DRUG EFFECT; METABOLISM; PHOSPHORYLATION; RAT; SPRAGUE DAWLEY RAT; TOXICITY AND INTOXICATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; CISPLATIN; CYTOPROTECTION; ERYTHROPOIETIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; NEUROTOXICITY SYNDROMES; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 38449087047     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.6.1547     Document Type: Article

References (52)

1. Boulikas T and Vougiouka M: Cisplatin and platinum drugs at the molecular level. Oncol Rep 10: 1663-1682, 2003.
2. Quasthoff S and Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol 249: 9-17, 2002.
3. Meijer C, de Vries EG, Marmiroli P, Tredici G, Frattola L and Cavaletti G: Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicol 20: 883-887, 1999.
4. Jelkmann W: Erythropoietin after a century of research: younger than ever. Eur J Haematol 78: 183-205, 2007.
5. Brines M and Cerami A: Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 70: 246-250, 2006.
6. Digicaylioglu M and Lipton SA: Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades. Nature 412: 641-647, 2001.
7. Brines ML, Ghezzi P, Keenan S, et al: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97: 10526-10531, 2000.
8. Calapai G, Marciano MC, Corica F, et al: Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 401: 349-356, 2000.
9. Siren AL, Fratelli M, Brines M, et al: Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 98: 4044-4049, 2001.
10. Digicaylioglu M, Kaul M, Fletcher L, Dowen R and Lipton SA: Erythropoietin protects cerebrocortical neurons from HIV-1/gp120-induced damage. Neuroreport 15: 761-763, 2004.
11. Gorio A, Gokmen N, Erbayraktar S, et al: Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 99: 9450-9455, 2002.
12. Erbayraktar S, Grasso G, Sfacteria A, et al: Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 100: 6741-6746, 2003.
13. Bianchi R, Buyukakilli B, Brines M, et al: Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA 101: 823-828, 2004.
14. Savino C, Pedotti R, Baggi F, et al: Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol 172: 27-37, 2006.
15. Orhan B, Yalcin S, Nurlu G, Zeybek D and Muftuoglu S: Erythropoietin against cisplatin-induced peripheral neurotoxicity in rats. Med Oncol 21: 197-203, 2004.
16. Bianchi R, Brines M, Lauria G, et al: Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin Cancer Res 12: 2607-2612, 2006.
17. Bianchi R, Gilardini A, Rodriguez-Menendez V, et al: Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur J Cancer 43: 710-717, 2007.
18. Ohigashi T, Yoshioka K and Fisher JW: Autocrine regulation of erythropoietin gene expression in human hepatocellular carcinoma cells. Life Sci 58: 421-427, 1996. (Pubitemid 26186637)
19. Acs G, Acs P, Beckwith SM, et al: Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61: 3561-3565, 2001.
20. McBroom JW, Acs G, Rose GS, Krivak TC, Mohyeldin A and Verma A: Erythropoietin receptor function and expression in epithelial ovarian carcinoma. Gynecol Oncol 99: 571-577, 2005.
21. Dagnon K, Pacary E, Commo F, et al: Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res 11: 993-999, 2005.
22. Khuri FR: Weighing the hazards of erythropoiesis stimulation in patients with cancer. New Engl J Med 356: 2445-2448, 2007.
23. Kozar K, Kaminski R, Legat M, et al: Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int J Oncol 24: 1149-1157, 2004.
24. Issat T, Nowis D, Legat M, et al: Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. Int J Oncol 30: 1413-1425, 2007.
25. Golab J, Nowis D, Skrzycki M, et al: Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem 278: 407-414, 2003.
26. Nowis D, Legat M, Grzela T, et al: Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene 25: 3365-3374, 2006.
27. Gozdz A, Habas A, Jaworski J, et al: Role of N-methyl-D-aspartate receptors in the neuroprotective activation of extracellular signal-regulated kinase 1/2 by cisplatin. J Biol Chem 278: 43663-43671, 2003.
28. Kim YK, Kim HJ, Kwon CH, et al: Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. J Appl Toxicol 25: 374-382, 2005.
29. Boogaerts M, Coiffier B and Kainz C: Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 88: 988-995, 2003.
30. Littlewood TJ: The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 28: 49-53, 2001.
31. Osterborg A, Brandberg Y, Molostova V, et al: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 20: 2486-2494, 2002.
32. Wright JR, Ung YC, Julian JA, et al: Randomized, double-blind, placebo-controlled trial of erythropoietin in non-smallcell lung cancer with disease-related anemia. J Clin Oncol 25: 1027-1032, 2007.
33. Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23: 5960-5972, 2005.
34. Henke M, Laszig R, Rube C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260, 2003.
35. Bohlius J, Wilson J, Seidenfeld J, et al: Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98: 708-714, 2006.
36. Brown WM, Maxwell P, Graham AN, et al: Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells 25: 718-722, 2007.
37. Elliott S, Busse L, Bass MB, et al: Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107: 1892-1895, 2006.
38. Osterborg A, Aapro M, Cornes P, Haselbeck A, Hayward CR and Jelkmann W: Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 43: 510-519, 2007.
39. Masuda S, Nagao M, Takahata K, et al: Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 268: 11208-11216, 1993.
40. Erbayraktar S, Yilmaz O, Gokmen N and Brines M: Erythropoietin is a multifunctional tissue-protective cytokine. Curr Hematol Rep 2: 465-470, 2003.
41. Campana WM, Li X, Shubayev VI, Angert M, Cai K and Myers RR: Erythropoietin reduces Schwann cell TNF-alpha, Wallerian degeneration and pain-related behaviors after peripheral nerve injury. Eur J Neurosci 23: 617-626, 2006.
42. Campana WM and Myers RR: Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury. FASEB J 15: 1804-1806, 2001.
43. Jansen CE, Miaskowski C, Dodd M, Dowling G and Kramer J: A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 104: 2222-2233, 2005.
44. Steeghs N, de Jongh FE, Sillevis-Smitt PA and van den Bent MJ: Cisplatin-induced encephalopathy and seizures. Anticancer Drugs 14: 443-446, 2003.
45. Chu CT, Levinthal DJ, Kulich SM, Chalovich EM and DeFranco DB: Oxidative neuronal injury. The dark side of ERK1/2. Eur J Biochem 271: 2060-2066, 2004.
46. Alessandrini A, Namura S, Moskowitz MA and Bonventre JV: MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc Natl Acad Sci USA 96: 12866-12869, 1999.
47. Wang X, Wang H, Xu L, et al: Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis. J Pharmacol Exp Ther 304: 172-178, 2003.
48. Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK and Cheng AL: Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem Biophys Res Commun 63: 1423-1430, 2002.
49. Mitsuma W, Ito M, Kodama M, et al: Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis. Biochem Biophys Res Commun 344: 987-994, 2006.
50. Cuzzocrea S, Mazzon E, di Paola R, et al: Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse. Arthritis Rheum 52: 940-950, 2005.
51. Villa P, Bigini P, Mennini T, et al: Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198: 971-975, 2003.
52. Cuzzocrea S, Mazzon E, Di Paola R, et al: Erythropoietin reduces the development of experimental inflammatory bowel disease. J Pharmacol Exp Ther 311: 1272-1280, 2004.